Clinical Trial Update: Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab plus temozolomide (Temodar) and erlotinib (Tarceva) in glioblastoma and gliosarcoma; the study is completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tarceva (erlotinib)
• Temodar (Temozolomide)

Snippet

Sponsor: University of California, San Francisco | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-14